Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.
Click here

Addressing The Unmet Need of Ocular Pain

EyeCool Therapeutics is committed to delivering fast, lasting relief for patients suffering from Chronic Ocular Surface Pain (COSP)

Learn More

Our Focus

COSP is a newly defined, often misdiagnosed condition marked by persistent eye pain, burning, dryness, and discomfort—even when no clinical signs are visible. First described as a distinct disease state by Galor et al. in 2022, COSP has been shown to be as disabling as fibromyalgia or migraine, yet no FDA-approved treatments exist.1

  1. Galor A, Hamrah P, Haque S, Attal N, Labetoulle M. Understanding chronic ocular surface pain: An unmet need for targeted drug therapy. The Ocular Surface. 2022;26:148–156.

~14M

~14M

The esimated number of U.S. adults suffering from COSP, a condition with no FDA-approved therapies

47%

47%

The approximate percentage of patients living with COSP that experience moderate to severe symptoms

76%

76%

Percentage of COSP patients reporting overall impact to their quality of life as moderate, severe or extreme

5th

5th

Population-level ranking of the “top five” reasons for eye care visits based on prevalence of diagnostic claims